Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSERT-EXT long-term odevixibat in Alagille syndrome
2021-000996-36Phase 3Active
- Sponsor
- Albireo Pharma
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in Alagille syndrome (ALGS), sponsored by Albireo Pharma. Primary endpoint: Change in scratching from baseline through Week 72. Started Jun 2021; status: active.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on 2021-000996-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000996-36.